Drug intelligence / Profile preview

SHR-2106

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

SHR-2106 is a monoclonal antibody drug developed by Guangdong Hengrui Pharmaceutical. It is currently in Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics after single intravenous or subcutaneous administration in healthy subjects. It is being investigated for use in kidney transplant patients and for the treatment of active primary dry syndrome (likely referring to Sjögren's syndrome). There are currently no similar products approved for sale globally.

Beyond the preview

Go deeper on SHR-2106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2106.

Explore the full profile